RESUMEN
We sought to study the time course of the distribution of valproate (VPA) to subdural cerebrospinal fluid (CSF) in relation to subcutaneous extracellular fluid (ECF) and plasma after a single oral dose and to study the distribution to these three compartments under steady-state conditions. Microdialysis was used to estimate unbound VPA concentrations in subdural CSF and subcutaneous ECF, and blood samples were drawn for estimation of total and unbound VPA plasma concentrations in four patients with drug-resistant partial epilepsy undergoing presurgical evaluation with subdural EEG monitoring. Three patients were given a single oral dose of VPA, and one patient was receiving regular VPA treatment. VPA was analyzed by gas chromatography with flame ionization detection. The distribution of VPA to subdural CSF was rapid (Tmax, 3.5 h in two patients and 5.5 h in one patient) and subject to a minor delay in all three patients compared with that in the subcutaneous tissue ECF (Tmax, 2.5 h in all three patients), which in turn exhibited no evidence of a distribution delay compared with plasma. Subdural CSF levels of VPA were slightly lower than subcutaneous ECF levels (mean ratio, 0.78) and unbound plasma levels (mean ratio, 0.91). VPA rapidly enters the subdural CSF in unbound concentrations marginally lower than those obtained in subcutaneous ECF and plasma. These findings provide a pharmacokinetic rationale for acute administration of VPA. The good correlation between VPA concentrations in subcutaneous ECF and subdural CSF indicates that estimation of unbound VPA concentrations in subcutaneous tissue using microdialysis sampling has the potential to be useful for monitoring purposes.
Asunto(s)
Anticonvulsivantes/farmacocinética , Epilepsias Parciales/metabolismo , Microdiálisis/estadística & datos numéricos , Ácido Valproico/farmacocinética , Administración Oral , Adulto , Anticonvulsivantes/sangre , Anticonvulsivantes/líquido cefalorraquídeo , Barrera Hematoencefálica/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Líquido Cefalorraquídeo/química , Líquido Cefalorraquídeo/metabolismo , Electroencefalografía/estadística & datos numéricos , Epilepsias Parciales/tratamiento farmacológico , Espacio Extracelular/química , Espacio Extracelular/metabolismo , Femenino , Humanos , Masculino , Monitoreo Fisiológico/estadística & datos numéricos , Espacio Subdural/química , Espacio Subdural/metabolismo , Ácido Valproico/sangre , Ácido Valproico/líquido cefalorraquídeoRESUMEN
PURPOSE: Our objective was to compare the efficacy and safety of gabapentin and vigabatrin as first-line add-on treatment in patients with partial epilepsy. METHODS: This was a multicenter, double-blind, randomized dose titration study. After baseline assessment and randomization, the dose could be increased if seizures persisted and reduced if side effects occurred. Health-related quality of life was assessed at baseline and at the end of the study. By a protocol amendment post hoc, all randomized patients were offered a standardized perimetry examination at the end of the study. Improvement rate was the proportion of patients with a reduction of seizure frequency of at least 50% during an 8-week period without any adverse events causing withdrawal. RESULTS: One hundred two patients were randomized and analyzed on an intent-to-treat basis. The improvement rate was 48% in the gabapentin group and 56% in the vigabatrin group. The improvement rate, when per protocol criteria were fulfilled, was 57% in the gabapentin group and 59% in the vigabatrin group. The proportion of seizure-free patients was 31% in the gabapentin group and 39% in the vigabatrin group. There was no difference in quality-of-life scores between the groups. Perimetry after termination of the study on 64 patients showed abnormal results in 3 of 32 patients in the vigabatrin group. CONCLUSION: Approximately one third of the patients in both groups became seizure-free. Although no major differences were seen in terms of the improvement rate between the groups, equivalence between the two drugs was not found.
Asunto(s)
Acetatos/uso terapéutico , Aminas , Anticonvulsivantes/uso terapéutico , Ácidos Ciclohexanocarboxílicos , Epilepsias Parciales/tratamiento farmacológico , Vigabatrin/uso terapéutico , Ácido gamma-Aminobutírico , Acetatos/administración & dosificación , Adolescente , Adulto , Anciano , Anticonvulsivantes/administración & dosificación , Niño , Método Doble Ciego , Esquema de Medicación , Quimioterapia Combinada , Femenino , Gabapentina , Humanos , Masculino , Persona de Mediana Edad , Proyectos de Investigación , Estudios Retrospectivos , Resultado del Tratamiento , Vigabatrin/administración & dosificaciónRESUMEN
PURPOSE: To estimate topiramate (TPM) concentrations in subdural cerebrospinal fluid (CSF), subcutaneous extracellular fluid (ECF), and plasma and to study the correlation of TPM concentrations in these three different compartments. METHODS: In this single case study of a patient with drug-resistant partial epilepsy undergoing presurgical evaluation with subdural EEG monitoring, we used microdialysis to estimate concentrations of unbound TPM in CSF of the subdural space and ECF of abdominal subcutaneous tissue. Blood samples were drawn for estimation of TPM concentrations in plasma. RESULTS: The correlation between unbound TPM concentrations in subdural CSF and abdominal subcutaneous ECF was good. The mean ratio of ECF/CSF TPM concentration was 0.93 (SD+/-0.03) and the correlation coefficient was 0.98. The mean ratio of ECF/total plasma TPM was 0.75 (SD+/-0.06), and the correlation coefficient was 0.99. The mean ratio of CSF/total plasma TPM was 0.81 (SD+/-0.06), and the correlation coefficient was 0.97. CONCLUSIONS: Assuming a protein binding of TPM of approximately 13%. it is concluded that, based on nine microdialysis samples from a single subject, TPM levels in the CSF at the cortical surface are approximately the same as the unbound plasma levels. Additional patients should be studied to confirm the results.
Asunto(s)
Anticonvulsivantes/farmacocinética , Epilepsias Parciales/líquido cefalorraquídeo , Epilepsias Parciales/tratamiento farmacológico , Espacio Extracelular/metabolismo , Fructosa/análogos & derivados , Plasma/metabolismo , Piel/metabolismo , Espacio Subdural/metabolismo , Adulto , Anticonvulsivantes/líquido cefalorraquídeo , Anticonvulsivantes/uso terapéutico , Epilepsias Parciales/metabolismo , Espacio Extracelular/química , Femenino , Fructosa/líquido cefalorraquídeo , Fructosa/farmacocinética , Fructosa/uso terapéutico , Humanos , Microdiálisis , Plasma/química , Piel/química , Espacio Subdural/química , TopiramatoRESUMEN
This article is the second in a series of studies aimed at monitoring valproic acid pharmacokinetics in patients with epilepsy by subcutaneous microdialysis. In the current study, a detailed investigation on healthy volunteers is made of the relationship between total concentrations in plasma, free concentrations in plasma, and dialysate concentrations. Particular emphasis is put on validating that the in vivo recovery under standard conditions (30 mm dialyzing membrane and 0.5 microl/minute perfusion rate) is sufficiently close to 100%. It was found that the recovery was very close to 100% at 0.5 microl/minute and by in vitro studies it could be excluded that valproic acid binds to the dialysis equipment. The correlation between unbound plasma concentrations and microdialysis concentrations of valproic acid was acceptable (r = 0.80), and they did not differ systematically from one another. It is concluded that microdialysis can be used to sample subcutaneous extracellular valproic acid in a clinical setting giving reliable estimates of the unbound concentration in plasma.
Asunto(s)
Anticonvulsivantes/sangre , Monitoreo de Drogas/métodos , Microdiálisis/métodos , Ácido Valproico/sangre , Cromatografía de Gases , Humanos , Valores de Referencia , Sensibilidad y Especificidad , Factores de TiempoRESUMEN
Standardised skin biopsies followed by immunohistochemical examination for the presence of terminal nerve fibres reacting for neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) were evaluated. Healthy subjects regularly displayed free nerve endings of both fibre types in the papillary and reticular dermis. Both fibre types were present close to blood vessels, while CGRP immunoreactive fibres were more often encountered near sweat gland acini compared to SP fibres. Diabetes mellitus complicated by polyneuropathy was accompanied by marked reduction of SP and CGRP reactive fibres in the dermis layers. Five type I diabetes patients without clinical or neurophysiological evidence of polyneuropathy also had reduced density of both fibre types, being significant for CGRP fibres when compared with controls. Skin biopsy with immunohistochemical staining for neuropeptides may represent a sensitive tool in evaluation of patients with peripheral neuropathies.